<DOC>
	<DOC>NCT01061723</DOC>
	<brief_summary>Primary objective: - to evaluate the efficacy of Sarilumab in patients with Ankylosing Spondylitis [AS] using the Assessment in AS working group criteria [ASAS] 20% response criteria [ASAS20] Secondary objectives: - to demonstrate that Sarilumab is effective on: - assessment of higher level of response (ASAS 40% response criteria [ASAS40]) - partial remission - disease activity - range of motion - Magnetic Resonance Imaging [MRI] of the spine - to assess the safety and tolerability of Sarilumab in patients with AS as well as the pharmacokinetic profile of Sarilumab in patients with AS</brief_summary>
	<brief_title>Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description>The duration of participation in this study for each patient was approximately 22 weeks; including up to 4 weeks screening period, 12-week double-blind treatment period and 6-week safety follow-up period.</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<criteria>Inclusion criteria: Diagnosis AS according to the New York modified criteria Patient must have an adequate trial of at least 2 different Non Steroidal AntiInflammatory Drugs [NSAIDs] taken for at least 2 weeks in each case and, on a stable dose for ≥2 weeks or be intolerant to NSAIDs Patient must have active AS for ≥3 months before screening and active disease must be present at screening and at baseline; Active AS being defined by: Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score of ≥4 (Numerical Rating Scale 010) Total back pain score ≥4 (Numerical Rating Scale 010) Patients treated with corticosteroid must be on a stable dose for ≥2 weeks prior to baseline Patients treated with the Disease Modifying AntiRheumatic Drugs [DMARDs] hydroxychloroquine, sulfasalazine and methotrexate (MTX) must be on stable dose ≥12 weeks prior to baseline Exclusion criteria: &lt;18 years old or ≥75 years old Complete fusion of the spine Past history of non response to any antiTumor Necrosis Factors [TNFs] treatment or non response to any other biological treatment for AS Any past or current treatment with antiTNF's or any biological agent within 3 months prior to screening Treatment with DMARDs except for hydroxychloroquine, sulfasalazine and MTX MTX &gt;25 mg/week hydroxychloroquine &gt;400 mg/day Sulfasalazine &gt;3 g/day Treatment with oral prednisone or equivalent corticosteroids &gt;10 mg/day within 6 weeks prior to screening Use of intramuscular or intraarticular corticosteroids within the last 4 weeks before screening Previous treatment with cyclosporine, azathioprine The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>